ESGO/ESTRO/ESP guidelines for the management of endometrial carcinoma (2021)
The European gynaecological oncology, radiotherapy and pathology societies' joint guideline integrates molecular classification into risk groups for endometrial cancer and sets adjuvant treatment for each, including no adjuvant therapy for early POLE-mutated tumours.
Overview
Joint evidence-based guideline covering diagnosis, molecular classification, surgical staging including sentinel node mapping, risk group definitions incorporating molecular class, adjuvant radiotherapy and chemotherapy recommendations, fertility-sparing treatment, and management of advanced and recurrent disease.
The adjuvant recommendations on this site's endometrial subtype pages (observation for stage I to II POLE-mutated disease, chemotherapy for p53-abnormal tumours with myometrial invasion, brachytherapy for intermediate risk) follow this guideline.
- Some molecular-based de-escalation recommendations await confirmation from the RAINBO trials.
Similar pages
not linked directly; found by shared links- TrialPORTEC-2
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
- Key paperConfirmation of ProMisE: a genomics-based clinical classifier for endometrial cancer
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
- TrialFIRES & SENTOR (sentinel node mapping)
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
- IdeaMolecular-class-directed adjuvant therapy in endometrial cancer
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
- TermHysterectomy
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
- TermEndometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
- TrialPORTEC-3
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.